Biomea Fusion, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Biomea Fusion, Inc. (BMEA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $2.35 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-05
- Biomea Fusion, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $3.79, a 67.27% decline year-over-year.
- Biomea Fusion, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $11.58, a 20.50% increase year-over-year.
- Biomea Fusion, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $9.61, a 3.44% increase year-over-year.
- Biomea Fusion, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $9.29, a 45.35% decline year-over-year.
- Biomea Fusion, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $9.82, a 25.44% decline from fiscal 2024.
- Biomea Fusion, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $13.17, a 18.22% increase from fiscal 2023.
- Biomea Fusion, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $11.14, a 13.17% decline from fiscal 2022.
- Biomea Fusion, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $12.83, a 46.46% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.35 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | $3.79 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | $9.82 10-K · filed 2026-03-24 | |||
| 2025-09-30 | $9.76 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | $10.01 10-Q · filed 2025-08-05 | |||
| 2025-03-31 | $11.58 10-Q · filed 2025-05-05 | |||
| 2024-12-31 | $13.17 10-K · filed 2025-03-31 | |||
| 2024-09-30 | $13.06 10-Q · filed 2024-10-29 | |||
| 2024-06-30 | $12.04 10-Q · filed 2024-07-31 | |||
| 2024-03-31 | $9.61 10-Q · filed 2024-05-02 | |||
| 2023-12-31 | $11.14 10-K · filed 2024-03-28 | |||
| 2023-09-30 | $12.39 10-Q · filed 2023-10-30 | |||
| 2023-06-30 | $9.29 10-Q · filed 2023-07-31 | |||
| 2023-03-31 | $9.29 10-Q · filed 2023-05-02 | |||
| 2022-12-31 | $12.83 10-K · filed 2023-03-28 | |||
| 2022-09-30 | $13.19 10-Q · filed 2022-11-07 | |||
| 2022-06-30 | $14.81 10-Q · filed 2022-08-01 | |||
| 2022-03-31 | $17.00 10-Q · filed 2022-05-16 | |||
| 2021-12-31 | $8.76 10-K · filed 2022-02-28 | |||
| 2021-09-30 | $6.60 10-Q · filed 2021-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |